| Literature DB >> 31611482 |
Irene Sacristán1, Michael Sieg2, Francisca Acuña3, Emilio Aguilar3, Sebastián García3, María José López3, Aitor Cevidanes1, Ezequiel Hidalgo-Hermoso4, Javier Cabello5,6, Thomas W Vahlenkamp2, Javier Millán7, Elie Poulin8,9, Constanza Napolitano8,10.
Abstract
Owned, free-roaming domestic cats are abundant in the Chilean countryside, having high probability of contact with wildlife and potentially participating as reservoirs of zoonotic pathogens. In the present study, 131 cats from two remote study areas (Valdivia and Chiloe Island) in southern Chile were analyzed for infection/exposure to eight pathogens. Serum samples from 112 cats were tested for antigens against feline leukemia virus (FeLV antigen-ELISA) and antibodies against feline immunodeficiency virus (FIV-ELISA) and canine distemper virus (CDV-serum neutralization), yielded occurrence of 8.9, 1.7 and 0.8% respectively. The presence of DNA of five vector-borne pathogens, piroplasmids, Ehrlichia spp., Anaplasma spp., Rickettsia spp. and Bartonella spp. was investigated in thirty cats. Overall observed occurrence was 6.6% (2/30) for both Anaplasma platys, and B. henselae, and 3.3% (1/30) for both Bartonella sp. and Theileria equi. Observed occurrence for all vector-borne pathogens in Valdivia area was significantly higher than in Chiloe Island (5/15 vs 0/15; P=0.04). Our results represent the first description of exposure to CDV and DNA detection of T. equi and A. platys in domestic cats in Chile. The results highlight the importance of performing pathogen screening in owned, free-roaming rural cats to evaluate their potential role as reservoirs of infection and vectors for disease transmission to wildlife.Entities:
Keywords: PCR; feline and canine virus; rural free-roaming domestic cat; serology; vector-borne pathogen
Mesh:
Substances:
Year: 2019 PMID: 31611482 PMCID: PMC6943315 DOI: 10.1292/jvms.19-0208
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Fig. 1.Study area. Rural communities near protected areas of Valdivia, Los Ríos region, and Chiloe Island, Los Lagos region, in southern Chile.
Primers used in pathogen detection, target genes amplified and size of the amplified product for each pathogen using real time PCR
| Pathogen | Region amplified | Primer Forward (5′-3′) | Primer Reverse (5′-3′) | Final [primer] ( | PCR product (bp) |
|---|---|---|---|---|---|
| 16S rRNA | GCAAGCYTAACACATGCAAGTCG | CTACTAGGTAGATTCCTAYGCATTACTCACC | 0.5 | 102a) | |
| Piroplasmid | 18S rRNA | GACGATCAGATACCGTCGTAGTCC | CAGAACCCAAAGACTTTGATTTCTCTC | 0.3 | 114a) |
| ITS1 | GCTCGATTGRTTTACTTTGCTGTGAG | CATGCTATAACCACCAAGCTAGCAATAC | 0.5/0.3 | 300a) | |
| ITS1 | AGATGATGATCCCAAGCCTTCTG | CCTCCGACCTCACGCTTATCA | 0.3 | 180a) |
a) Targeted size could vary depending on the species.
PCR results with correlated serological results and clinical signs information
| Sample | Clinical signs | Location | Sex | Age | FIV-ELISA | FeLV-ELISA | CDV-IFT/SNT | Piro-plasmid | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16046 | Asymptomatic | Chiloe Island | Female | Adult | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| 15221 | Asymptomatic | Valdivia | Female | Adult | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| 15225 | Asymptomatic | Valdivia | Female | Adult | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| 15226 | Asymptomatic | Valdivia | Female | Adult | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| 15007 | Asymptomatic | Chiloe Island | Male | Adult | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| 15231 | Asymptomatic | Valdivia | Male | Adult | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| 15240 | Valdivia | Male | Adult | Negative | Negative | Negative | Negative | Negative | Negative | |||
| 16011 | Chiloe Island | Female | Adult | Negative | Negative | Negative | Negative | Negative | Negative | Negative | ||
| 15004 | Chiloe Island | Female | Adult | Negative | Negative | Negative | Negative | Negative | Negative | Negative | ||
| 15002 | Asymptomatic | Chiloe Island | Female | Adult | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 16013 | Asymptomatic | Chiloe Island | Female | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 16014 | Asymptomatic | Chiloe Island | Female | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15029 | Asymptomatic | Chiloe Island | Female | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15191 | Asymptomatic | Valdivia | Female | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15207 | Asymptomatic | Valdivia | Female | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15212 | Asymptomatic | Valdivia | Female | Juvenile | NE | NE | NE | Negative | Negative | Negative | Negative | |
| 15223 | Asymptomatic | Valdivia | Female | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15227 | Asymptomatic | Valdivia | Female | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 16031 | Asymptomatic | Chiloe Island | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 16037 | Asymptomatic | Chiloe Island | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15014 | Asymptomatic | Chiloe Island | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15022 | Asymptomatic | Chiloe Island | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15030 | Asymptomatic | Chiloe Island | Male | Juvenile | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15034 | Chiloe Island | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative | |
| 15038 | Asymptomatic | Chiloe Island | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15184 | Asymptomatic | Valdivia | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | |
| 15195 | Ocular secretion | Valdivia | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15201 | Asymptomatic | Valdivia | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
| 15203 | Asymptomatic | Valdivia | Male | Adult | NE | NE | NE | Negative | Negative | Negative | Negative | Negative |
NE, not explored; FIV, feline immunodeficiency virus; FeLV, feline leukemia virus; CDV, canine distemper virus.
Molecular and serological screening results of pathogens in owned, free-roaming domestic cats. Pathogen occurrence by study area and sex
| Serology | Molecular analyses | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELISA | IFA/SNT | Piroplasmida | |||||||||||||||||||||
| FeLV | FIV | CDV | |||||||||||||||||||||
| n/total | % | 95%CI | n | % | 95%CI | n/total | % | 95%CI | n/total | % | 95%CI | n/total | % | 95%CI | n/total | % | 95%CI | n/total | % | 95%CI | |||
| Area | |||||||||||||||||||||||
| Valdivia | 1/37 | 2.7 | 2.7–8.1 | 0/37 | 0.0 | 0.0 | 1/37 | 2.7 | 1.6–2.7 | 1/15 | 6.6 | 7.6–20.9 | 3/15 | 20.0 | 2.9–42.9 | 2/15 | 13.3 | 6.1–32.82 | 0/15 | 0.0 | 0.0 | 0.0 | |
| Chiloe | 9/75 | 12.0 | 3.7–32.7 | 2/75 | 2.6 | 1.0–6.3 | 0/75 | 0.0 | 0.0 | 0/15 | 0.0 | 0.0 | 0/15 | 0.0 | 0.0 | 0/15 | 0.0 | 0.0 | 0/15 | 0.0 | 0.0 | 0.0 | |
| Total | 10/112 | 8.9 | 3.5–14.2 | 2/112 | 1.7 | 0.7–4.2 | 1/112 | 0.8 | 0.08–2.6 | 1/30 | 3.3 | 3.4–10.15 | 3/30 | 10.0 | 1.3–21.39 | 2/30 | 6.6 | 2.8–16.14 | 0/30 | 0.0 | 0.0 | 0.0 | |
| Sex | |||||||||||||||||||||||
| Male | 4/47 | 8.5 | 0.2–16.7 | 0/47 | 0.0 | 0.0 | 1/47 | 2.1 | 2.1–6.4 | 0/14 | 0.0 | 0.0 | 1/14 | 7.1 | 8.2–22.5 | 2/14 | 14.2 | 6.6–35.2 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Female | 6/65 | 9.23 | 2.0–16.4 | 2/65 | 3.0 | 1.2–7.3 | 0/65 | 0.0 | 0.0 | 1/16 | 6.2 | 7.7–19.5 | 2/16 | 12.5 | 5.7–30.7 | 0/16 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
IFA, immunofluorescence assay; SNT, serum neutralization test; C.I.,Confidence intervals (lower-upper); FIV, feline immunodeficiency virus; FeLV, feline leukemia virus; CDV, canine distemper virus.